Amgevita Launch In Finland Is No Counterbalance For Remsima Loss, Orion Anticipates
Intensified competition and declining prices, coupled with a failure to scoop winner-takes-all tenders in certain Nordic markets, took a huge bite out of Orion’s biosimilars sales in 2018. Launching the first Humira biosimilar in Finland will not plug the gap, the company has stated.
You may also be interested in...
There is “no question that the overall biosimilar industry was too optimistic on the pricing of biosimilars, at least in the European context”, according to Orion’s president and chief executive officer, Timo Lappalainen.
Amgen and Orion have struck a sales and marketing collaboration for the US firm’sAmgevita (adalimumab) biosimilar in Finland. The deal for “Finland’s first adalimumab biosimilar” comes as Amgen competes with Biogen, Mylan and Sandoz to take market share in Europe away from AbbVie’s Humira reference brand after the arthritis blockbuster lost its supplementary protection certificate (SPC) monopoly in mid- October (Generics bulletin, 26 October 2018, page 1).
Orion has during October started to ship in Europe its Flusarion Easyhaler alternative to GlaxoSmithKline’s Seretide (salmeterol/ fluticasone) asthma therapy. And the Finnish firm is also conducting bioequivalence studies with a view to using its Easyhaler dry-powder inhaler (DPI) device to offer a rival to Boehringer Ingelheim’s Spiriva (tiotropium) chronic obstructive pulmonary disease (COPD) blockbuster.